R&D Real progress in the fight against Alzheimer’s disease These are encouraging times in Alzheimer’s disease research and treatment.
News Alzheimer's biotech Korsana to go public via reverse merger By merging with Cyclerion, Korsana will get a Nasdaq listing and additional cash to develop its new-generation amyloid-targeting drug for Alzheimer's.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
